Towards a new tuberculosis drug: pyridomycin – nature's isoniazid
OPEN ACCESS
Loading...
Author / Producer
Date
2012-10-01
Publication Type
Journal Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Rights / License
Abstract
Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA‐inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an important source of antibiotics including potent anti‐tuberculosis agents. Here, we describe pyridomycin, a compound produced by Dactylosporangium fulvum with specific cidal activity against mycobacteria. By selecting pyridomycin‐resistant mutants of Mycobacterium tuberculosis, whole‐genome sequencing and genetic validation, we identified the NADH‐dependent enoyl‐ (Acyl‐Carrier‐Protein) reductase InhA as the principal target and demonstrate that pyridomycin inhibits mycolic acid synthesis in M. tuberculosis. Furthermore, biochemical and structural studies show that pyridomycin inhibits InhA directly as a competitive inhibitor of the NADH‐binding site, thereby identifying a new, druggable pocket in InhA. Importantly, the most frequently encountered isoniazid‐resistant clinical isolates remain fully susceptible to pyridomycin, thus opening new avenues for drug development.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
4 (10)
Pages / Article No.
1032 - 1042
Publisher
EMBO Press
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Drug discovery; InhA; Isoniazid; Pyridomycin; Tuberculosis
Organisational unit
03647 - Altmann, Karl-Heinz (emeritus) / Altmann, Karl-Heinz (emeritus)
Notes
Funding
260872 - More Medicines for Tuberculosis (EC)